Loading patent…
AssigneeEli Lilly and Company
InventorsDennis R. Berry, Anne H. Dantzig, Manuel Debono, Robert Hamill, R. Michael Molloy, Raymond C. Yao
Estimating the term…
Fermentation product A87689 is produced by a strain of Amycolatopsis mediterranei selected from NRRL 18815 and NRRL 18851, or an A87689-producing mutant thereof. A87689, its C.sub.1-6 -alkyl ether and C.sub.1-6 -alkanoyl ester derivatives and pharmaceutically acceptable salts thereof are phospholipase A.sub.2 inhibitors that are useful as antiinflammatory agents. Fermentation products known as BU-3889V, its components and pharmaceutically acceptable salts thereof, are phospholipase A.sub.2 inhibitors that are also useful as antiinflammatory agents.
A method of inhibiting PLA.sub.2 activity in animals which comprises administering a PLA.sub.2 -inhibiting amount of a compound selected from A87689, which in its calcium salt form has the following characteristics:
A method of treating arthritic disease in animals which comprises administering to said animal a compound selected from A87689, which in its calcium salt form has the following characteristics:
A method of treating asthma in animals which comprises administering to said animal an amount of a compound selected from A87689, which in its calcium salt form has the following characteristics:
A method of inhibiting PLA.sub.2 activity in animals which comprises administering a PLA.sub.2 -inhibiting amount of at least one compound selected from the group consisting of BU-3889V A.sub.1, BU-3889V A.sub.2, BU-3889V A.sub.3, BU-3889V D.sub.1, BU-3889V D.sub.2, BU-3889V D.sub.3, or a pharmaceutically acceptable salt thereof, to said animal.
A method of reducing inflammation in animals which comprises administering to said animal an inflammation-inhibiting amount of at least one compound selected from the group consisting of BU-3889V A.sub.1, BU-3889V A.sub.2, BU-3889V A.sub.3, BU-3889V D.sub.1, BU-3889V D.sub.2, BU-3889V D.sub.3, or a pharmaceutically acceptable salt thereof.
A method of treating arthritic disease in animals which comprises administering to said animal an effective amount of at least one compound selected from the group consisting of BU-3889V A.sub.1, BU-3889V A.sub.2, BU-3889V A.sub.3, BU-3889V D.sub.1, BU-3889V D.sub.2, BU-3889V D.sub.3, or a pharmaceutically acceptable salt thereof.
A method of treating asthma in animals which comprises administering to said animal an amount of at least one compound selected from the group consisting of BU-3889V A.sub.1, BU-3889V A.sub.2, BU-3889V A.sub.3, BU-3889V D.sub.1, BU-3889V D.sub.2, BU-3889V D.sub.3, or a pharmaceutically acceptable salt thereof, sufficient to reduce the inflammation of an asthmatic animal's respiratory system.
A method of reducing inflammation in an animal which comprises administering to said animal an inflammation inhibiting amount of a compound selected from the group consisting of
Dependencies are inferred from the claim text.